Acute myeloid leukaemia (AML) is an uncommon, rapidly progressive neoplasm in dogs. The aim of this retrospective study was to characterize the clinical presentation, haematologic findings, diagnostic imaging results, treatment and survival time of a contemporary cohort of dogs with AML. Diagnosis was based on >20% blasts in bone marrow or blood identified as myeloid based on morphologic findings, flow cytometric immunophenotyping and cytochemical staining.
| INTRODUCTION
Acute myeloid leukaemia (AML) is a haematopoietic neoplasm characterized by the accumulation (>20%) of immature myeloid cells ("blasts") in the bone marrow.
1 Although AML is rare, it is the most common form of acute leukaemia in dogs. [2] [3] [4] [5] Mutations in several genes and aberrant DNA methylation patterns have been associated with specific variants of AML in people. 6 In dogs with AML, mutations in oncogenes such as FLT3, C-KIT, and RAS and abnormal DNA methylation have also been observed, suggesting that dogs share similar oncopathogenic pathways to human beings. 7, 8 Revised classification schemes in human patients now incorporate genetic or epigenetic findings; however, tests for these abnormalities are not performed routinely in veterinary medicine. 9 There have been several case series of dogs with acute leukaemia that include information on signalment, presenting signs, physical examination findings, and haematologic and phenotyping results. 2, 5, [10] [11] [12] [13] [14] These case series include dogs with AML, acute lymphoblastic leukaemia (ALL) and possibly some dogs with leukemic phase of lymphoma. These studies only used immunophenotyping (generally with flow cytometry) to classify the leukemias, which may be problematic in some dogs with AML, which can lack expression of differentiation-associated antigens and only express stem cell markers on immunophenotyping. 3, 15 Thus, results could have been skewed by inclusion of dogs with AML in ALL groups or vice versa.
There is little information on the outcome and prognosis of dogs with AML, although the disease is generally assumed to have a poor prognosis. One of the aforementioned retrospective studies described prognostic factors, treatment, and outcome of 71 dogs with acute leukaemia. 2 However, this study included a large proportion of cases (24%) that could not be phenotyped with certainty and were termed "acute undifferentiated leukaemia." Due to the rarity of canine AML and the lack of published data focused on this haematopoietic neoplasm, an efficacious chemotherapeutic protocol has not been identified. In order to better characterize and therefore understand this neoplasm, the aim of our retrospective study was to characterize the clinical presentation, haematologic findings, diagnostic imaging results, treatment and survival time of a contemporary cohort of dogs with AML. 
| MATERIALS AND METHODS

| RESULTS
Records from 37 dogs were reviewed. Two dogs were excluded because neither flow cytometric analysis nor cytochemical staining were performed (male, castrated; n = 1) or the blast count in blood (12%) did not achieve AML classification criteria and no bone marrow sample was obtained (female, spayed; n = 1). Haematologic findings are summarized in Table 2 . Common findings were leukocytosis (due to increased numbers of blasts), anaemia and thrombocytopenia. The anaemia was non-regenerative (absolute reticulocyte count within reference intervals) in 83% (24/29) of anae- those that received symptomatic care only (P < .0001) using the log b A CBC with a differential count was not performed on 1 dog.
c Four dogs had a platelet count that was too low for accurate enumeration.
with AML. [17] [18] [19] We were underpowered to perform such categorical comparisons in our cohort of dogs and thus did not evaluate these.
When evaluating peripheral blood blast count as a continuous variable, we did not detect any differences between treatment groups (P = .3420, Table 3 ). In contrast to our results, Novacco et al found that a neutrophil count within the reference interval was associated with increased survival. 2 As that case series reported outcome data for dogs with multiple types of acute leukaemia, of which only 32%
were AML, their result may not be reflective of the biology of canine AML. Ultimately, treatment bias and the small number of dogs in our study likely hampered our ability to detect any associations between the other selected covariables and overall survival.
The three dogs in our study with the longest overall survival (>100 days) received different treatments, that is, symptomatic care plus prednisone or symptomatic care plus chemotherapy and prednisone. These prolonged survival times suggest that AML may have an unpredictable biologic behaviour and that there may be subtypes that are less aggressive, as evident in human beings. [20] [21] [22] It is also possible An interesting and important clinical finding in our study is that a substantial proportion of affected dogs (74%) had peripheral lymphadenopathy on physical examination. In previous canine AML case series, peripheral lymphadenopathy has been reported as uncommon, 5, 11, 12 and lymphadenopathy is infrequently mentioned in case reports. [23] [24] [25] [26] [27] [28] [29] [30] [31] Indeed, in some studies of dogs with acute leukaemia, animals with moderate to severe lymphadenopathy were excluded from analysis in an attempt to differentiate and exclude dogs with lymphoma from those with acute leukaemia. Given that interpretation of these test results is subjective and that aberrant expression of lymphoid markers can occur in AML, it is possible some dogs in our study would have been assigned a different lineage by other diagnosticians. The "diagnostic conundrum" that is often encountered when performing lineage classification of canine acute leukemias has been well described elsewhere. 3 In human medicine, WHO criteria have been developed to define acute leukemias that defy obvious lineage classification ("mixed-phenotype acute leukaemia"), although this category generally represents less than 5% of acute leukemias. 35, 36 Limited reagents exist for lineage classification in veterinary medicine and we elected to be inclusive rather than exclusive in our study population in order to provide a broad understanding of disease pathology. We elected not to use a category of "acute undifferentiated leukaemia" or "acute leukaemia" so as not to inaccurately imply correlation or similarities to previous studies using this terminology. 2, 14 Similarly, as the goal of our study was to describe the clinical features of AML in dogs, we did not attempt to propose new classification schemes or to define a category consistent with "mixed-phenotype acute leukaemia." Defining this entity is certainly a consideration for future research. Well-powered studies will be necessary to understand the prognostic implications of aberrant expression or mixed phenotypes in dogs with acute leukemias.
Surprisingly, a large number of dogs in our study (71%) were male. Novacco et al also found a male preponderance (55%), although percentages were only reported for all acute leukemias, not AML specifically. 2 To a more extreme degree, our results parallel what has been found in human medicine, where acute leukemias (AML, ALL) and lymphomas are more common in males. [37] [38] [39] [40] [41] [42] It is unclear why this epidemiologic difference occurs, although modification of risk in females based on a genetic linkage to ABO genes has been proposed. 41 To truly define the risk of AML in male dogs, a study with appropriate control populations is needed.
The limitations of our study stem from its retrospective design.
The total number of included dogs is small (albeit substantial for this rare disease) and led to even smaller treatment groups, which may contribute to the lack of statistical significance with regards to multiple categorical and continuous variable comparisons. The treatment protocols were not standardized and treatment with chemotherapy was done at the discretion of the owners and attending veterinarians, which likely involved bias, as discussed above. Also, treatment varied greatly among dogs in the chemotherapeutic group; therefore conclusions cannot be made in regards to which type of chemotherapeutic drug combination was most efficacious. We did, however, document haematologic responses to prednisone, Ara-C, and doxorubicin in multiple dogs.
In conclusion, our study is the first to describe the treatment and 
